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The final two sessions of the meeting addressed the question
of whether current drug development programmes for new
agents in breast cancer are realising their full potential.
Dr Stephen Johnston gave an overview of the scenario and
outlined how, in an era of molecular pathology and targeted
therapies, the challenges facing both academic investigators
and the pharmaceutical industry are indeed significant.
Despite the preclinical promise that many novel therapeutics
have shown, translating that promise into significant patient
benefit does not always happen. The traditional clinical
development pathway where one size fits all no longer
applies to modern targeted therapies, as exemplified by the
lessons we have learnt form HER2 targeting with both trastu-
zumab and, more recently, lapatinib. Combination strategies
that address the complexity of the integrative networks on
which these molecular targets impact are now emerging.
Dr Robert Clarke examined some of the principles behind the
preclinical development that are needed to bring a new
molecule from early discovery and synthesis through to first-
in-man clinical studies. As the human genome is unravelled,
the major challenge faced by scientists is the multitude of at
least 500 drug targets in cancer, and the vast complex of
interdependent networks on which each target impacts.
Compensatory pathways that become operative when a given
target is blocked can severely limit the development of a
potent inhibitor of what seems like a very suitable oncogenic
target. As such, effective combinations are much more likely
to be effective than individual targeted drugs, and early
assessment of safety and toxicity in preclinical in vivo models
will remain necessary. Efficacy testing of these drugs in
xenograft models, however, does not always reflect the
heterogeneity of human breast cancer – and the concept of
early phase zero trials as proof of concept may be an
effective way to anticipate failure and to reject ineffective
drugs before larger scale clinical development is triggered.
Professor David Cameron discussed some of the principles
of founder clinical trials in breast cancer, and challenged
some of the current thinking around the design of phase II/III
trials for novel targeted therapies. The key dilemma lies
between selecting patients for a novel drug based on some
predefined clinical criteria or molecular biomarker in the
tumour, or treating all comers and powering the trial for
benefit in predefined stratified groups. While the former has a
higher likelihood of success, recruitment may be slower and
clinical benefit in other groups could be missed. On the other
hand, the larger more pragmatic clinical trial remains
expensive and a higher risk, yet may yield otherwise unknown
information about the benefit of a new therapy in certain
groups of patients.
Professor John Robertson described the development of
small molecule tyrosine kinase inhibitors targeted against the
epidermal growth factor receptor in breast cancer. The
preclinical rationale was strong – namely that epidermal
growth factor receptor expression was enhanced in models
of acquired endocrine resistance and that gefitinib may be
effective in tamoxifen-resistant disease, or when combined
with endocrine therapy to delay development of acquired
resistance. While the efficacy of gefitinib in monotherapy
studies in advanced disease was disappointing, neoadjuvant
presurgical studies with both gefitinib and erlotinib
demonstrated clear biological effects with the drugs in
oestrogen receptor-positive breast cancer. The most recent
clinical trials of endocrine therapy combined with gefitinib
were reviewed. Appropriate target identification and selection
have limited the successful development of epidermal growth
factor receptor inhibitors, and while activating mutations have
proved crucial in understanding benefit in lung cancer, the
same has never been demonstrated in breast cancer.
Dr Serena Di Cosimo discussed the emerging data regarding
mammalian target of rapamycin (mTOR) antagonists, and the
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phosphatidylinositol-3-kinase/Akt pathway in particular, as a
viable target in breast cancer. Promising preclinical data
demonstrated that blockade of this target in oestrogen
receptor-positive breast cancer could enhance endocrine
responsiveness, which supported the development of clinical
trials in breast cancer combining aromatase inhibitors with
mTOR antagonists – while a large-scale phase III trial in
metastatic disease was negative, a preoperative neoadjuvant
study with detailed biomarker analyses identified added
benefit in tumours with activating PI3CA exon 9 mutations.
Furthermore, understanding that mTOR antagonism released
an important negative feedback loop that then activated Akt
via insulin-like growth factor receptor substrate 1 has led to
new combination strategies emerging – in particular, using an
insulin-like growth factor-1 receptor antibody in addition to an
mTOR antagonist. As such, mTOR blockade could still be an
important strategy in breast cancer once the most effective
combinations have been developed.
There then followed an open forum and discussion session in
which the speakers were joined by three senior represen-
tatives from the pharmaceutical industry (Maria Koehler, Ian C
Smith, Ajay Bhatnagar), all of whom have been involved in
development of novel therapies for breast cancer. The
challenges faced by the industry were debated, including the
complex issue of how to prioritise development of molecules
in a scenario where numerous targets and potential lead
compounds now exist. Approaches to clinical trial design that
may allow the most effective agents to be identified early
were discussed, in addition to how modern platforms that
provide a molecular profile of human breast cancer could be
integrated into early-phase clinical development. Collabora-
tion between the pharmaceutical industry, academic institu-
tions and clinical investigators will clearly remain crucial if the
new era of targeted therapies is to be translated into signifi-
cant gains in clinical outcome for women with breast cancer.
The session concluded with a plenary lecture from Dr Dennis
Slamon, who outlined the lessons we had learnt from the
identification and successful targeting of the HER2 oncogene
in breast cancer. Central to this was the ability to measure the
target in human breast cancer appropriately and to select the
patients who would derive the most benefit. He outlined
some of the current challenges that we face in assay
development for any new target, and how molecular
pathology needs to be integrated into early-phase trial design
in order to maximise the potential of the numerous new
agents that are now available for clinical investigation.
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